FROM this month more women
with postmenopausal osteoporosis
will be able to receive
reimbursement for Prolia
(denosumab) following an
expanded listing on the
Pharmaceutical Benefit Scheme.
As such, Prolia (denosumab) is
now listed on the PBS as the sole
anti-resorptive agent for:
established postmenopausal
osteoporosis in a woman with
fracture due to minimal trauma;
and osteoporosis in women aged
70 years of age and older with a
Bone Mineral Density (BMD) Tscore
of -2.5 or less.The above article was sent to subscribers in Pharmacy Daily's issue from 09 Aug 12 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 09 Aug 12
THE Australian Commission on Safety and Quality in Health Care has today launched a national Standard to improve the care of people with cognitive disabilities or impairments.
AUSTRALIAN mothers and their babies experienced some positive outcomes during the early years of the pandemic, new research from the Australian Institute of Health and Welfare (AIHW) has discovered.
AUSTRALIA needs more pharmacists than ever, in the face of an ageing population and rising healthcare demands, according to the Pharmaceutical Society of Australia (PSA).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.